Posts

SenzaGen reinforces its sales organization – recruiting Peter Sandberg

SenzaGen has recruited Peter Sandberg as Director of Sales. Peter has long experience from a number of positions and companies active in the life science sector in the last thirty years. By recruiting Peter Sandberg SenzaGen strengthens its sales organization and the commercial development of the company.

With the base at Medicon Village in Lund SenzaGen develops and implements animal free allergy tests of chemicals and proteins, especially for the cosmetic and pharmaceutical industry. SenzaGen’s test GARD (Genomic Allergen Rapid Detection) has been developed over 15 years and measure significantly more parameters than existing tests on the market. It makes GARD a safer and more effective test than other options. GARD eliminates the need for animal testing and enables customers to develop and provide safer consumer products as well as offer their employees a better working environment.

“SenzaGen is in an expansive phase at the moment, and we see an increased interest in allergy tested and safe products in the cosmetic and pharmaceutical market. The recruitment of Peter Sandberg will allow us to meet market interest and substantially increase our sales activities”, says Anki Malmborg Hager, CEO of SenzaGen.

Peter Sandberg has a B.Sc. in Genetics and has worked primarily with sales, product launches and branding, for over thirty years. With experience from BioInvent, self-employment in the GTF AB and Celltox AB Peter Sandberg helped to build and develop a variety of companies and has a wide network of contacts throughout the industry. Peter Sandberg comes from Fisher Scientific’s Nordic operations, where he was General Manager for many years where he built up sales operations.

“SenzaGen is an exciting company and GARD is a product with great potential. So when I got the chance to contribute, it felt as exciting challenge. I believe that my experience in combination with SenzaGen’s innovation can generate new opportunities for the future, says Peter Sandberg”, new Director of Sales at SenzaGen AB.

For more information:
Anki Malmborg Hager, CEO, SenzaGen AB
E-mail: amh@senzagen.com
Phone: +46 768 284822

Peter Sandberg, Director of sales SenzaGen AB
E-mail: peter.sandberg@senzagen.com
Phone: +46 708 204481
About SenzaGen
SenzaGen provides in vitro testing for cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company’s unique test GARD is based on research from the Department of Immune Technology at Lund University.

 

About GARD
By analyzing between 200-389 markers instead of 1-2, which competing methods does, GARD delivers results with 90% accuracy. This compared with the golden standard, animal tests on mice, which results in only 72% accuracy. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance is an allergen. Existing tests does not achieve sufficient accuracy and lack the ability to measure the potency of a substance.

Ian Kimber joins the board of SenzaGen AB

SenzaGen AB, a diagnostic spin-off company from Lund University, is proud to announce that Prof. Ian Kimber will join the Board of Directors.

SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

Prof Ian Kimber is currently Professor of Toxicology and Associate Dean for Business Development in the Faculty of Life Sciences at the University of Manchester. He has broad research interests at the interface between toxicology and immunology, with a particular focus on allergy and inflammation.  Professor Kimber holds, and has held, a variety of positions on national and international expert and scientific advisory committees. Currently these include the following:  Member UK Medicines and Healthcare products Regulatory Agency (MHRA) Committee for Safety of Devices, Programme Advisor Food Standards Agency Food Allergy and Intolerance Research Programme, and member MRC Translational Research Group. Professor Kimber was previously President of the British Toxicology Society (BTS) (2012-2014), and Chairman of the Board of the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (2008-2013).  

“I am delighted to be joining the Board of SenzaGen at such an exciting period of growth. Since our initial studies that led to the development and ultimate validation of the Local Lymph Node Assay I have maintained a keen interest in chemical allergy and in the development of novel approaches for improved hazard identification and risk assessment. In this respect harnessing fully the opportunities afforded by developments in the biomedical sciences is critical, and the work of SenzaGen in exploiting a genomic approach to pathway analysis and risk assessment is at the cutting edge of new developments”, says Prof Kimber.

Ian Kimber has published over 600 research papers, review articles and book chapters, and serves currently on the editorial boards of toxicology, immunology, dermatology and pathology journals.

“We are very happy to have Prof Kimber on board in SenzaGen”, since he is one of the forerunners in sensitization testing, says Prof Carl Borrebaeck, “his knowledge and interest in the field of allergy and replacement of animal testing with new technologies is very important to us. We value his participation in developing the next generation tests.”

Hanna Frykman new Market Coordinator at SenzaGen

SenzaGen continues its expansion and is setting up a sales and marketing organisation. In this process SenzaGen recruits Hanna Frykman as a marketing coordinator.

Most recently, Hanna comes from the Royal Academy of Sciences, where she worked as an information coordinator and scientific secretary of an EU project. Hanna has experience as communicator and project manager, and has been working with startup companies. She is one of the developers of the cultural business project Thomanders Jul in Lund.

– It is extremely exciting to be working with a company in this early stage and to build up the business from scratch, says Hanna Frykman.

Hanna begins in SenzaGen in March 2015 and will focus on developing graphical profile and work with sales and marketing at SenzaGen.

– The combination of science and business thinking and her ability to build up network was been instrumental in the recruitment of Hanna. I very much look forward to working together with Hanna, says Anki Malmborg Hager, CEO of SenzaGen

Maria Agemark new quality manager at SenzaGen

SenzaGen is in an expansive phase and is building up its team with new personnel. Maria Agemark has been recruited as quality manager and was previously working at the Department Immunotechnology at LTH . Maria has a PhD in biochemistry, where she conducted research on the Aquaporins in humans and plants.

– It is going to be exciting and challenging to work in a new company that is in an exciting early phase. I know the research behind the products well and look forward to be part of the new team that SenzaGen is setting up, says Maria Agemark .

Maria starts on SenzaGen in March 2015 and will focus on building up the new lab and quality systems.

– Maria has an expertise that we need to bring the company to the next level. I very much look forward to working together with Maria, says Anki Malmborg Hager, CEO of SenzaGen.